Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Verinata Health's verifi® Prenatal Test Available through the California Prenatal Screening Program

Published: Tuesday, November 05, 2013
Last Updated: Tuesday, November 05, 2013
Bookmark and Share
verifi® prenatal test will be available to pregnant women in California.

Illumina, Inc. has announced that the verifi® prenatal test, offered by Verinata Health, an Illumina company, will be available to pregnant women in California through the state's Prenatal Screening Program.

The availability of the verifi® prenatal test represents a major advance in prenatal screening, providing pregnant women with genetic information about their babies without the risk associated with invasive testing such as amniocentesis or chorionic villus sampling (CVS).

Beginning today, all pregnant women in California at increased risk of carrying a fetus with trisomy 21 (Down syndrome) or trisomy 18 (Edwards syndrome), or who have had an ultrasound showing a large nuchal translucency, will have the option of receiving a non-invasive prenatal test.

"As a designated prenatal diagnosis center, we evaluated all of the different non-invasive prenatal tests, and selected the verifi® prenatal test based on the fact it provides the fastest turnaround time at three to six days, the lowest test failure rate at less than one percent, and an exceptionally responsive staff," said Dr. Art Karimi, Director of the Institute of Prenatal Diagnosis and Reproductive Genetics.

Women screening positive who desire a non-invasive prenatal test will be referred to a designated state-approved Prenatal Diagnostic Center, many of whom have elected to offer the verifi® prenatal test for their patients. The California Prenatal Screening Program screens nearly 400,000 women annually and is the largest prenatal screening program in the world.

"California is the first state to prioritize broad non-invasive prenatal testing as a secondary screening option for high-risk pregnant women," said Vance Vanier, M.D., Vice President of Global Commercial Operations for Verinata. "We applaud the state of California for their leadership through this comprehensive Prenatal Screening Program and we are pleased to bring reliable results from the verifi® prenatal test to women throughout the state."

The California Prenatal Screening Program is conducted through the state of California Genetic Disease Screening Program. The voluntary Prenatal Screening Program was established to provide pregnant women with improved screening for genetic disorders.

California offers the only comprehensive prenatal screening program that includes follow-up for all non-negative test results, non-invasive prenatal testing and/or confirmatory testing through either amniocentesis or CVS, when indicated.

In cases where a genetic disorder is detected prenatally, managing the high-risk pregnancy and ensuring delivery in a hospital with a Neonatal Intensive Care Unit with the appropriate level of care provides optimal patient outcomes for these families.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Illumina Acquires Advanced Liquid Logic
Acquisition a key component in the development of complete sample-to-answer solutions for next-generation sequencing.
Wednesday, July 24, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
BGI Purchases 128 Illumina HiSeq™ 2000 Sequencing Systems
Acquisition puts Beijing Genomics Institute on path to become world's largest sequencing facility.
Thursday, January 14, 2010
Expression Analysis Purchases its First Illumina Genome Analyzer
Illumina's Genome Analyzer sequencing technology will support EA's new plant and animal genomic services.
Friday, January 09, 2009
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!